Pfizer PFE Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| —— | $8.06B— | —— | $31.41B+42.6% | ||
| $6.59B-6.0% | $7.01B+11.5% | $6.29B+24.2% | $5.06B-2.4% | ||
| $799M-8.9% | $877M+67.0% | $525M-39.8% | $872M-26.2% | ||
| -$2.13B-1.5% | -$2.1B+38.9% | -$3.44B+10.0% | -$3.83B+10.9% | ||
| $263M+141% | $109M+131% | -$347M-33.0% | -$261M-107% | ||
| -$561M-166% | $854M-26.9% | $1.17B+97.8% | $591M-47.5% | ||
| -$469M+54.2% | -$1.02B-241% | -$300M-125% | $1.19B-4.1% | ||
| -$1.29B+61.9% | -$3.38B-610% | $663M-85.3% | $4.51B+326% | ||
| -$3.67B-17.7% | -$3.12B-624% | $595M+141% | -$1.45B-108% | ||
| -$2.81B-109% | -$1.35B-37.0% | -$982M-80.2% | -$545M+53.3% | ||
| $12.29B-3.6% | $12.74B— | —— | $29.27B-10.2% | ||
| $2.63B-9.6% | $2.91B-25.5% | $3.91B+20.7% | $3.24B+19.4% | ||
| -$1.35B— | —— | -$33.17B-110% | -$15.78B+30.0% | ||
| -$10.9B+36.4% | -$17.14B— | —— | —— | ||
| $41M— | —— | -$40M+75.8% | -$165M-180% | ||
| —— | —— | —— | -$1.52B— | ||
| $2.74B-15.1% | $3.23B+45.7% | $2.22B+53.6% | $1.44B-1.7% | ||
| -$469M+54.2% | -$1.02B-241% | -$300M-125% | $1.19B-4.1% | ||
| -$2.81B-109% | -$1.35B-37.0% | -$982M-80.2% | -$545M+53.3% | ||
| —— | —— | —— | —— | ||
| -$1.29B+61.9% | -$3.38B-610% | $663M-85.3% | $4.51B+326% | ||
| $470M-79.2% | $2.26B-35.3% | $3.49B— | —— | ||
| —— | —— | $0— | $0— | ||
| $786M— | —— | $787M— | —— | ||
| $5.27B+24.2% | $4.24B+24.5% | $3.41B+520% | $550M+99.3% | ||
| —— | -$2M— | —— | $200M— | ||
| $14.36B+41.7% | $10.13B-67.3% | $30.97B-14.9% | $36.38B-5.4% | ||
| $17.96B+335% | $4.13B-89.5% | $39.26B-12.4% | $44.82B+63.3% | ||
| $1.1B-30.3% | $1.57B-20.7% | $1.98B+209% | $641M-1.2% | ||
| —— | —— | $0— | $0— | ||
| —— | —— | $0— | $0— | ||
| —— | —— | -$5.17B— | —— | ||
| $9.77B+2.7% | $9.51B+2.9% | $9.25B+2.9% | $8.98B+2.9% | ||
| -$458M+2.3% | -$469M+25.7% | -$631M— | —— | ||
| —— | —— | $3.37B+1,616% | -$222M-131% | ||
| —— | $11.23B+374,100% | $3M-99.9% | $3.89B— | ||
| —— | $178M— | —— | $54M— | ||
| $4.69B+30.0% | $3.61B+14.6% | $3.15B-60.0% | $7.87B+5.9% | ||
| —— | $9.84B+105% | $4.79B-81.6% | $26.03B-12.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Pfizer generate?
- Pfizer (PFE) generated $12.6B in operating cash flow over the trailing twelve months.
- What is Pfizer's free cash flow?
- After $2.5B of capital expenditures, Pfizer's free cash flow was $12.5B over the trailing twelve months, up 26.6% year over year.
- Where does Pfizer's cash flow data come from?
- Every line is extracted from Pfizer's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
